Market Research Logo

Ocular Pain - Pipeline Review, H2 2016

Ocular Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H2 2016’, provides an overview of the Ocular Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Ocular Pain
    • The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects
    • The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Ocular Pain
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Ocular Pain
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Ocular Pain Overview
    Therapeutics Development
    Pipeline Products for Ocular Pain - Overview
    Ocular Pain - Therapeutics under Development by Companies
    Ocular Pain - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Ocular Pain - Products under Development by Companies
    Ocular Pain - Companies Involved in Therapeutics Development
    D. Western Therapeutics Institute, Inc.
    InSite Vision Incorporated
    Kala Pharmaceuticals, Inc.
    Ocular Therapeutix, Inc.
    Reata Pharmaceuticals, Inc.
    Sylentis S.A.U.
    Valeant Pharmaceuticals International, Inc.
    Ocular Pain - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (bromfenac sodium + dexamethasone acetate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bromfenac sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dexamethasone acetate SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Ocular Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISV-705 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ketorolac tromethamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    loteprednol etabonate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    loteprednol etabonate next generation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-71 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-72 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omaveloxolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RX-10045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SYL-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ocular Pain - Dormant Projects
    Ocular Pain - Product Development Milestones
    Featured News & Press Releases
    Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite
    Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
    Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit
    Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite
    Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery
    May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
    Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite
    Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
    Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
    Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
    Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
    Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery
    Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling
    Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Ocular Pain, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Ocular Pain - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016
    Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2016
    Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
    Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H2 2016
    Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
    Ocular Pain - Pipeline by Sylentis S.A.U., H2 2016
    Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Ocular Pain - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Ocular Pain, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report